

# Jinhai Medical Technology Limited

## 今海醫療科技股份有限公司

(Incorporated in the Cayman Islands with members' limited liability)

(於開曼群島註冊成立的成員有限責任公司)

(Stock Code 股份代號: 2225)

### NOTIFICATION LETTER 通知信函

26 April 2024

Dear Registered Shareholders,

#### **Jinhai Medical Technology Limited (the "Company")**

#### **– Notice of Publication of Annual Report 2023 (the "Current Corporate Communications")**

The English and Chinese versions of the Company's Current Corporate Communications are available on the Company's website at [www.jin-hai.com.hk](http://www.jin-hai.com.hk) and the website of The Stock Exchange of Hong Kong Limited (the "HKEx's website") at [www.hkexnews.hk](http://www.hkexnews.hk) respectively (the "Website Version"). You may access the Current Corporate Communications by clicking "Investor Relations" on the home page of the Company's website or by searching under "Listed Company Information" on the website of HKEX. Viewing the above documents requires Adobe® Reader®. The Company strongly recommends you to access the Website Version of the Current Corporate Communications and all future Corporate Communications<sup>(1)</sup>.

You may at any time choose to receive Corporate Communications free of charge either in printed form, or read the Website Version; and either in English language version only, Chinese language version only or both language versions, notwithstanding any wish to the contrary you may have previously conveyed to the Company. If you wish to receive the Current Corporate Communications in printed form or change your choice of means of receipt of the Corporate Communications, please complete the Request Form on the reverse side of this letter and return it to the Company c/o Boardroom Share Registrars (HK) Limited (the "Hong Kong Branch Share Registrar"), the branch share registrar of the Company in Hong Kong, by using the mailing label at the bottom of the Request Form (no need to affix a stamp if posted in Hong Kong; otherwise, please affix an appropriate stamp). The address of the Hong Kong Branch Share Registrar is 2103B, 21/F, 148 Electric Road, North Point, Hong Kong. You may also send an email with a scanned copy of the Request Form to [jinhai@boardroomlimited.com](mailto:jinhai@boardroomlimited.com). The Request Form may also be downloaded from the Company's website at [www.jin-hai.com.hk](http://www.jin-hai.com.hk) or the HKEx's website at [www.hkexnews.hk](http://www.hkexnews.hk).

It is the responsibility of you to provide a functional email address. If you have not provided your email address to the Company or need to update your email address, the Company recommends you provide your email address by completing, signing the enclosed Request Form and returning it to the Hong Kong Branch Share Registrar at the above-mentioned address by post or by email to [jinhai@boardroomlimited.com](mailto:jinhai@boardroomlimited.com). If the Company does not have your functional email address, until such time that the functional email address is provided to the Hong Kong Branch Share Registrar, you will be unable to receive via email notices of publication of the Website Version of Corporate Communications (the "Notice of Publication") and Actionable Corporate Communications<sup>(2)</sup> in electronic form. As such, the Company would only be able to send you the Notice of Publication and the Actionable Corporate Communications in printed form.

Should you have any queries relating to any of the above matters, please call the Company's telephone hotline at (852) 2153 1688 during business hours from 9:00 a.m. to 5:00 p.m. Monday to Friday, excluding public holidays or send an email to [jinhai@boardroomlimited.com](mailto:jinhai@boardroomlimited.com).

Yours faithfully,  
For and on behalf of  
**Jinhai Medical Technology Limited**  
Chen Guobao  
Chairman of the Board and executive Director

**Note 1:** Corporate Communications include any document(s) issued or to be issued by the Company for the information or action of holders of any of its securities or the investing public, including but not limited to (a) the directors' report and its annual accounts together with a copy of the independent auditor's report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) the quarterly report, if any; (d) a notice of meeting; (e) a listing document; (f) a circular; and (g) a proxy form.

**Note 2:** Actionable Corporate Communications refer to any corporate communications that seek instructions from the Shareholders of the Company on how they wish to exercise their rights or make elections as Shareholders of the Company.

各位登記股東：

#### **今海醫療科技股份有限公司(「本公司」)**

#### **– 2023 年度報告(「本次公司通訊文件」)之發佈通知**

本公司的本次公司通訊文件中、英文版本已上載於本公司網站 [www.jin-hai.com.hk](http://www.jin-hai.com.hk) 及香港交易及結算有限公司網站(「香港交易所網站」) [www.hkexnews.hk](http://www.hkexnews.hk) (「網站版本」)。請在本公司網站主頁按「投資者關係」一項或在香港交易所網站於「上市公司公告」項下搜尋，以瀏覽是次公司通訊。以上文件須使用 Adobe® Reader® 開啟。本公司建議閣下閱覽本公司本次公司通訊及日後公司通訊<sup>(1)</sup>的網站版本。

儘管閣下早前曾向本公司作出公司通訊文件收取方式或語言版本的選擇，但仍可以隨時更改有關選擇，轉為以印刷本或網上方式收取及只收取英文印刷本、或只收取中文印刷本；或同時收取中、英文印刷本，費用全免。如閣下欲收取本次公司通訊文件之印刷本或更改已選擇的收取方式，請填妥在本信函背面的申請表格，並使用隨附之郵寄標籤經本公司的香港股份過戶登記分處寶德隆證券登記有限公司(「香港股份過戶登記分處」)寄回本公司(如在香港投寄，毋須貼上郵票；否則，請貼上適當的郵票)。香港股份過戶登記分處地址為香港北角電氣道148號21樓2103B室。閣下亦可把已填妥之申請表格的掃描副本電郵到 [jinhai@boardroomlimited.com](mailto:jinhai@boardroomlimited.com)。申請表格亦可於本公司網站 [www.jin-hai.com.hk](http://www.jin-hai.com.hk) 或香港交易所網站 [www.hkexnews.hk](http://www.hkexnews.hk) 內下載。

閣下有責任提供有效的電子郵件地址。如閣下尚未提供閣下之電子郵件地址予本公司，或需更新閣下之電子郵件地址，本公司建議閣下填妥及簽署隨附之申請表格，並按上述地址以郵寄方式交回本公司的香港股份過戶登記分處或以電子郵件方式發送至 [jinhai@boardroomlimited.com](mailto:jinhai@boardroomlimited.com)。如果本公司沒有收到閣下的有效電子郵件地址，閣下將無法透過電子郵件方式收取以電子方式發送的公司通訊網站版本的登載通知(「登載通知」)及可供採取行動的公司通訊。本公司只能以印刷本方式向閣下發送登載通知及可供採取行動的公司通訊<sup>(2)</sup>之印刷本予閣下，直至香港股份過戶登記分處收到閣下有效的電子郵件地址為止。

如閣下對本信函內容有任何疑問，請於辦公時間星期一至五(公眾假期除外)上午9時正至下午5時正致電本公司電話熱線(852) 2153 1688或電郵至 [jinhai@boardroomlimited.com](mailto:jinhai@boardroomlimited.com)。

代表  
今海醫療科技股份有限公司  
董事會主席兼執行董事  
陳國寶  
謹啟

2024年4月26日

**附註 1:** 公司通訊包括本公司發布或將予發布以供其任何證券持有人或投資大眾參照或採取行動的任何文件，其中包括但不限於 (a) 董事會報告，公司年度帳目連同獨立核數師報告以及(如適用)財務摘要報告；(b) 中期報告及(如適用)中期摘要報告；(c) 季度報告(如有)；(d) 會議通告；(e) 上市文件；(f) 通函；及(g) 代表委任表格。

**附註 2:** 可供採取行動的公司通訊是指任何涉及要求本公司股東指示其擬如何行使其有關本公司股東權利的公司通訊。

